Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.94 EUR | -2.02% | -8.92% | -45.43% |
Apr. 04 | AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada | MT |
Apr. 03 | AB Science: reconsideration possible for masitinib in ALS | CF |
Business Summary
Number of employees: 89
Sales per Business
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Protein Kinase Inhibitors
100.0
%
| 2 | 100.0 % | 1 | 100.0 % | -40.39% |
Sales per region
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
France
100.0
%
| 2 | 100.0 % | 1 | 100.0 % | -40.39% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 01-07-10 |
Laurent Guy
DFI | Director of Finance/CFO | - | 01-12-31 |
Chief Tech/Sci/R&D Officer | - | 18-03-31 | |
Alexis Bernard
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 01-07-10 |
Patrick Moussy
BRD | Director/Board Member | - | 01-07-10 |
Director/Board Member | 62 | 21-06-26 | |
Director/Board Member | 66 | 21-06-26 | |
Director/Board Member | - | 21-06-26 | |
Renaud Sassi
BRD | Director/Board Member | - | 21-06-26 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 49,567,190 | 32,740,001 ( 66.05 %) | 0 | 66.05 % |
Company contact information
Sector
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-45.43% | 108M | |
+5.73% | 71.48B | |
+11.60% | 9.18B | |
-15.34% | 4.79B | |
+34.54% | 3.98B | |
+5.09% | 3.97B | |
+27.76% | 2.56B | |
-28.33% | 2.29B | |
-24.15% | 2.23B | |
+6.23% | 1.92B |
- Stock Market
- Equities
- AB Stock
- Company AB Science